Twins and Dementia; CRISPR and Alzheimer’s; BTK Inhibitor Fails in MS Trials

Derick Alison
Derick Alison
2 Min Read

Dementia in one twin raised the risk of a shorter lifespan of a co-twin without dementia. (Alzheimer’s and Dementia)

Daily cocoa extract supplementation did not lead to overall cognitive function benefits compared with placebo, but subgroup analyses suggested possible benefits for people with poor diets. (American Journal of Clinical Nutrition)

CRISPR gene editing may open the door to alternative treatments for people whose Alzheimer’s disease is associated with genetic variants. (Nature)

Sanofi ended its agreement to acquire an exclusive license for an investigational glycogen synthase 1 inhibitor to treat Pompe disease from Maze Therapeutics after the Federal Trade Commission issued a complaint.

Cortical lesions and the central vein sign helped increase diagnostic accuracy for multiple sclerosis (MS), an analysis by the MAGNIMS study group showed. (JAMA Neurology)

The investigational Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib failed to meet its primary endpoint in the phase III EVOLUTION trials of relapsing MS, Merck KGaA said.

Boston University experts are examining brain tissue from the gunman involved in the recent Lewiston, Maine, mass shooting for signs of potential trauma related to his service in the Army Reserves. (AP)

Statin use moderated APOE’s and C-reactive protein’s associations with dementia. (Alzheimer’s and Dementia)

Photographs showed the true face of a woman with dementia, her daughter said. (Washington Post)

The Washington Post also profiled former Heisman trophy winners who subsequently were diagnosed with chronic traumatic encephalopathy (CTE).

  • Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more. Follow

Source link

Share this Article
Leave a comment